Providence, RI7 Active Studies

Essential Tremor Clinical Trials in Providence, RI

Find 7 actively recruiting essential tremor clinical trials in Providence, RI. Connect with local research sites and explore new treatment options.

7
Active Trials
7
Sponsors
1,672
Enrolling

Recruiting Essential Tremor Studies in Providence

About Essential Tremor Clinical Trials in Providence

Essential tremor is one of the most common movement disorders, causing involuntary shaking, most often in the hands. It is different from Parkinson's disease, though the two can be confused. Treatment includes medications, focused ultrasound, and deep brain stimulation for severe cases.

There are currently 7 essential tremor clinical trials recruiting participants in Providence, RI. These studies are seeking a combined 1,672 participants. Research is being sponsored by California Polytechnic State University-San Luis Obispo, Duke University, Women and Infants Hospital of Rhode Island and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Essential Tremor Clinical Trials in Providence — FAQ

Are there essential tremor clinical trials in Providence?

Yes, there are 7 essential tremor clinical trials currently recruiting in Providence, RI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Providence?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Providence research site will contact you about next steps.

Are clinical trials in Providence free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Providence studies also compensate for your time and travel.

What essential tremor treatments are being tested?

The 7 active trials in Providence are testing new therapies including novel drugs, biologics, and treatment approaches for essential tremor.

Data updated September 4, 2026 from ClinicalTrials.gov